Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy
Immune checkpoint inhibitors (ICI) have been revolutionary in the field of cancer therapy. However, their success is limited to specific indications and cancer types. Recently, the combination treatment of ICI and chemotherapy has gained more attention to overcome this limitation. Unfortunately, man...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1236965/full |
| _version_ | 1797690535361642496 |
|---|---|
| author | Yani Berckmans Jolien Ceusters Ann Vankerckhoven Roxanne Wouters Roxanne Wouters Matteo Riva Matteo Riva An Coosemans |
| author_facet | Yani Berckmans Jolien Ceusters Ann Vankerckhoven Roxanne Wouters Roxanne Wouters Matteo Riva Matteo Riva An Coosemans |
| author_sort | Yani Berckmans |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICI) have been revolutionary in the field of cancer therapy. However, their success is limited to specific indications and cancer types. Recently, the combination treatment of ICI and chemotherapy has gained more attention to overcome this limitation. Unfortunately, many clinical trials testing these combinations have provided limited success. This can partly be attributed to an inadequate choice of preclinical models and the lack of scientific rationale to select the most effective immune-oncological combination. In this review, we have analyzed the existing preclinical evidence on this topic, which is only limitedly available. Furthermore, this preclinical data indicates that besides the selection of a specific drug and dose, also the sequence or order of the combination treatment influences the study outcome. Therefore, we conclude that the success of clinical combination trials could be enhanced by improving the preclinical set up, in order to identify the optimal treatment combination and schedule to enhance the anti-tumor immunity. |
| first_indexed | 2024-03-12T02:00:51Z |
| format | Article |
| id | doaj.art-04cf28e71bf847afb875ab0b088ad270 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T02:00:51Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-04cf28e71bf847afb875ab0b088ad2702023-09-07T13:45:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-09-011410.3389/fimmu.2023.12369651236965Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapyYani Berckmans0Jolien Ceusters1Ann Vankerckhoven2Roxanne Wouters3Roxanne Wouters4Matteo Riva5Matteo Riva6An Coosemans7Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumDepartment of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumDepartment of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumDepartment of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumOncoinvent AS, Oslo, NorwayDepartment of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumDepartment of Neurosurgery, Centre Hospitalier Universitaire (CHU) UCLouvain Namur, University Hospital of Godinne, Yvoir, BelgiumDepartment of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, BelgiumImmune checkpoint inhibitors (ICI) have been revolutionary in the field of cancer therapy. However, their success is limited to specific indications and cancer types. Recently, the combination treatment of ICI and chemotherapy has gained more attention to overcome this limitation. Unfortunately, many clinical trials testing these combinations have provided limited success. This can partly be attributed to an inadequate choice of preclinical models and the lack of scientific rationale to select the most effective immune-oncological combination. In this review, we have analyzed the existing preclinical evidence on this topic, which is only limitedly available. Furthermore, this preclinical data indicates that besides the selection of a specific drug and dose, also the sequence or order of the combination treatment influences the study outcome. Therefore, we conclude that the success of clinical combination trials could be enhanced by improving the preclinical set up, in order to identify the optimal treatment combination and schedule to enhance the anti-tumor immunity.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1236965/fullimmune checkpoint inhibitorschemotherapypreclinical modelscombination treatmentcancer therapy |
| spellingShingle | Yani Berckmans Jolien Ceusters Ann Vankerckhoven Roxanne Wouters Roxanne Wouters Matteo Riva Matteo Riva An Coosemans Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy Frontiers in Immunology immune checkpoint inhibitors chemotherapy preclinical models combination treatment cancer therapy |
| title | Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy |
| title_full | Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy |
| title_fullStr | Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy |
| title_full_unstemmed | Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy |
| title_short | Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy |
| title_sort | preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy |
| topic | immune checkpoint inhibitors chemotherapy preclinical models combination treatment cancer therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1236965/full |
| work_keys_str_mv | AT yaniberckmans preclinicalstudiesperformedinappropriatemodelscouldhelpidentifyoptimaltimingofcombinedchemotherapyandimmunotherapy AT jolienceusters preclinicalstudiesperformedinappropriatemodelscouldhelpidentifyoptimaltimingofcombinedchemotherapyandimmunotherapy AT annvankerckhoven preclinicalstudiesperformedinappropriatemodelscouldhelpidentifyoptimaltimingofcombinedchemotherapyandimmunotherapy AT roxannewouters preclinicalstudiesperformedinappropriatemodelscouldhelpidentifyoptimaltimingofcombinedchemotherapyandimmunotherapy AT roxannewouters preclinicalstudiesperformedinappropriatemodelscouldhelpidentifyoptimaltimingofcombinedchemotherapyandimmunotherapy AT matteoriva preclinicalstudiesperformedinappropriatemodelscouldhelpidentifyoptimaltimingofcombinedchemotherapyandimmunotherapy AT matteoriva preclinicalstudiesperformedinappropriatemodelscouldhelpidentifyoptimaltimingofcombinedchemotherapyandimmunotherapy AT ancoosemans preclinicalstudiesperformedinappropriatemodelscouldhelpidentifyoptimaltimingofcombinedchemotherapyandimmunotherapy |